Vittorio Bellotti

List of Publications by Year
in descending order

179	10,706	41344	34986
papers	citations	49 h-index	98 g-index

185	185	185	8902
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The corona of proteinâ€“gold nanoparticle systems: the role of ionic strength. Physical Chemistry Chemical Physics, 2022, 24, 1630-1637.	2.8	5
2	AA amyloidosis without systemic inflammation: when clinical evidence validates predictions of experimental medicine. Kidney International, 2022, 101, 219-221.	5.2	0
3	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
4	Breakdown of supersaturation barrier links protein folding to amyloid formation. Communications Biology, 2021, 4, 120.	4.4	39
5	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres. Molecules, 2021, 26, 1913.	3.8	5
6	Topologically non-trivial metal-organic assemblies inhibit Î²2-microglobulin amyloidogenesis. Cell Reports Physical Science, 2021, 2, 100477.	5.6	1
7	Clinical ApoAâ€IV amyloid is associated with fibrillogenic signal sequence. Journal of Pathology, 2021, 255, 311-318.	4.5	4
8	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nature Communications, 2021, 12, 7112.	12.8	13
9	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. Journal of Biological Chemistry, 2020, 295, 11379-11387.	3.4	12
10	L444P Gba1 mutation increases formation and spread of Î±-synuclein deposits in mice injected with mouse Î±-synuclein pre-formed fibrils. PLoS ONE, 2020, 15, e0238075.	2.5	20
11	Lysozyme amyloid: evidence for the W64R variant by proteomics in the absence of the wild type protein. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 206-207.	3.0	6
12	Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. Clinical Chemistry and Laboratory Medicine, 2020, 58, 948-957.	2.3	20
13	A Narrative Review of the Role of Transthyretin in Health and Disease. Neurology and Therapy, 2020, 9, 395-402.	3.2	47
14	Title is missing!. , 2020, 15, e0238075.		0
15	Title is missing!. , 2020, 15, e0238075.		0
16	Title is missing!. , 2020, 15, e0238075.		0
17	Title is missing!. , 2020, 15, e0238075.		0
18	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. Journal of Medicinal Chemistry, 2019, 62, 8274-8283.	6.4	25

#	Article	IF	Citations
19	Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. Molecular Therapy, 2019, 27, 2111-2122.	8.2	120
20	The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. Journal of Pathology: Clinical Research, 2019, 5, 145-153.	3.0	46
21	C. elegans expressing D76N Î²2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis. Scientific Reports, 2019, 9, 19960.	3.3	14
22	Citrate stabilized gold nanoparticles interfere with amyloid fibril formation: D76N and Î”N6 Î²2-microglobulin variants. Nanoscale, 2018, 10, 4793-4806.	5.6	30
23	Conformational dynamics in crystals reveal the molecular bases for D76N beta-2 microglobulin aggregation propensity. Nature Communications, 2018, 9, 1658.	12.8	53
24	Interference of citrate-stabilized gold nanoparticles with Î²2-microglobulin oligomeric association. Chemical Communications, 2018, 54, 5422-5425.	4.1	11
25	Oleuropein aglycone: A polyphenol with different targets against amyloid toxicity. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1432-1442.	2.4	30
26	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.	3.4	68
27	The interaction of Î²2-microglobulin with gold nanoparticles: impact of coating, charge and size. Journal of Materials Chemistry B, 2018, 6, 5964-5974.	5.8	7
28	Citrate-stabilized gold nanoparticles hinder fibrillogenesis of a pathological variant of Î²₂-microglobulin. Nanoscale, 2017, 9, 3941-3951.	5.6	26
29	Î±-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. Journal of Biological Chemistry, 2017, 292, 6927-6937.	3.4	31
30	A specific nanobody prevents amyloidogenesis of D76N Î²2-microglobulin in vitro and modifies its tissue distribution in vivo. Scientific Reports, 2017, 7, 46711.	3.3	18
31	Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. Scientific Reports, 2017, 7, 182.	3.3	31
32	An Asp to Asn mutation is a toxic trigger in beta-2 microglobulin: structure and biophysics. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 15-16.	3.0	2
33	Antiamyloidogenic and proamyloidogenic chaperone effects of C-reactive protein and serum amyloid P component. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 28-29.	3.0	3
34	Protein aggregation. International Journal of Biological Macromolecules, 2017, 100, 1-2.	7.5	1
35	Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 229-237.	3.0	8
36	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. Journal of Proteomics, 2017, 165, 113-118.	2.4	14

#	Article	IF	Citations
37	Short-Chain Alkanethiol Coating for Small-Size Gold Nanoparticles Supporting Protein Stability. Magnetochemistry, 2017, 3, 40.	2.4	4
38	Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue Targeting. Frontiers in Molecular Biosciences, 2016, 3, 17.	3.5	19
39	Rational design of mutations that change the aggregation rate of a protein while maintaining its native structure and stability. Scientific Reports, 2016, 6, 25559.	3.3	47
40	Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro. Scientific Reports, 2016, 6, 29077.	3.3	22
41	Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. Biophysical Journal, 2016, 111, 2024-2038.	0.5	19
42	D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nature Communications, 2016, 7, 10353.	12.8	50
43	Amyloid persistence in decellularized liver: biochemical and histopathological characterization. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 1-7.	3.0	25
44	Molecular insights into cell toxicity of a novel familial amyloidogenic variant of Î²2â€microglobulin. Journal of Cellular and Molecular Medicine, 2016, 20, 1443-1456.	3.6	23
45	The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies. Journal of Nutritional Biochemistry, 2016, 30, 153-166.	4.2	39
46	Co-fibrillogenesis of Wild-type and D76N Î²2-Microglobulin. Journal of Biological Chemistry, 2016, 291, 9678-9689.	3.4	29
47	A novel mechanoâ€enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Molecular Medicine, 2015, 7, 1337-1349.	6.9	109
48	The H50Q Mutation Induces a 10-fold Decrease in the Solubility of Î±-Synuclein. Journal of Biological Chemistry, 2015, 290, 2395-2404.	3.4	65
49	Probing the Influence of Citrate-Capped Gold Nanoparticles on an Amyloidogenic Protein. ACS Nano, 2015, 9, 2600-2613.	14.6	80
50	Systemic Amyloidosis: Lessons from Î²2-Microglobulin. Journal of Biological Chemistry, 2015, 290, 9951-9958.	3.4	73
51	Bifunctional crosslinking ligands for transthyretin. Open Biology, 2015, 5, 150105.	3.6	2
52	Enhanced toxicity of silver nanoparticles in transgenicCaenorhabditis elegansexpressing amyloidogenic proteins. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 221-228.	3.0	9
53	Assessment of Cellular Responses after Short- and Long-Term Exposure to Silver Nanoparticles in Human Neuroblastoma (SH-SY5Y) and Astrocytoma (D384) Cells. Scientific World Journal, The, 2014, 2014, 1-13.	2.1	31
54	Class I Major Histocompatibility Complex, the Trojan Horse for Secretion of Amyloidogenic Î²2-Microglobulin. Journal of Biological Chemistry, 2014, 289, 3318-3327.	3.4	22

#	Article	IF	Citations
55	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1539-1544.	7.1	91
56	Rapid Proton-Detected NMR Assignment for Proteins with Fast Magic Angle Spinning. Journal of the American Chemical Society, 2014, 136, 12489-12497.	13.7	254
57	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 173-178.	3.0	24
58	Structure, Folding Dynamics, and Amyloidogenesis of D76N Î²2-Microglobulin. Journal of Biological Chemistry, 2013, 288, 30917-30930.	3.4	80
59	Reduction of conformational mobility and aggregation in W60G Î²₂â€microglobulin: assessment by ¹⁵N NMR relaxation. Magnetic Resonance in Chemistry, 2013, 51, 795-807.	1.9	10
60	Structure of an early nativeâ€like intermediate of Î²2â€microglobulin amyloidogenesis. Protein Science, 2013, 22, 1349-1357.	7.6	14
61	Monitoring the Interaction between Î²2-Microglobulin and the Molecular Chaperone Î±B-crystallin by NMR and Mass Spectrometry. Journal of Biological Chemistry, 2013, 288, 17844-17858.	3.4	32
62	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant Î²₂-Microglobulin. New England Journal of Medicine, 2012, 366, 2276-2283.	27.0	172
63	Nanotechnology drives a paradigm shift on protein misfolding diseases and amyloidosis. , 2012, , .		0
64	Smart conservation for the lazy consumer [Tech Life]. IEEE Spectrum, 2012, 49, 26-30.	0.7	2
65	Determining the Energy Landscape of Proteins by a Fast Isotope Exchange NMR Approach. Journal of the American Chemical Society, 2012, 134, 4457-4460.	13.7	9
66	Single-shot NMR measurement of protein unfolding landscapes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2012, 1824, 842-849.	2.3	7
67	Structure, Stability, and Aggregation of Î²-2 Microglobulin Mutants: Insights from a Fourier Transform Infrared Study in Solution and in the Crystalline State. Biophysical Journal, 2012, 102, 1676-1684.	0.5	31
68	Pathological Self-Aggregation ofb2-Microglobulin: A Challenge for Protein Biophysics. Sub-Cellular Biochemistry, 2012, 65, 165-183.	2.4	8
69	Fibrillogenesis of human Î²₂â€microglobulin in threeâ€dimensional silicon microstructures. Journal of Biophotonics, 2012, 5, 785-792.	2.3	8
70	A recurrent Dâ€strand association interface is observed in Î²â€2 microglobulin oligomers. FEBS Journal, 2012, 279, 1131-1143.	4.7	18
71	C. elegans Expressing Human Î²2-Microglobulin: A Novel Model for Studying the Relationship between the Molecular Assembly and the Toxic Phenotype. PLoS ONE, 2012, 7, e52314.	2.5	21
72	Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic Î²2-microglobulin variant. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1314-1319.	7.1	108

#	Article	IF	Citations
73	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 87-93.	3.8	22
74	Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. Journal of Molecular Biology, 2011, 407, 465-476.	4.2	48
75	Dâ€strand perturbation and amyloid propensity in betaâ€2 microglobulin. FEBS Journal, 2011, 278, 2349-2358.	4.7	13
76	The two tryptophans of Î²2-microglobulin have distinct roles in function and folding and might represent two independent responses to evolutionary pressure. BMC Evolutionary Biology, 2011, 11, 159.	3.2	16
77	Molecular dynamics simulation of Î²₂â€microglobulin in denaturing and stabilizing conditions. Proteins: Structure, Function and Bioinformatics, 2011, 79, 986-1001.	2.6	31
78	Enhanced molecular chaperone activity of the small heatâ€shock protein Î±Bâ€crystallin following covalent immobilization onto a solidâ€phase support. Biopolymers, 2011, 95, 376-389.	2.4	14
79	Effect of Tetracyclines on the Dynamics of Formation and Destructuration of Î²2-Microglobulin Amyloid Fibrils. Journal of Biological Chemistry, 2011, 286, 2121-2131.	3.4	87
80	The effects of an ideal Î²-turn on Î²-2 microglobulin fold stability. Journal of Biochemistry, 2011, 150, 39-47.	1.7	9
81	DEâ€loop mutations affect Î²2 microglobulin stability, oligomerization, and the lowâ€pH unfolded form. Protein Science, 2010, 19, 1386-1394.	7.6	43
82	Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 2010, 468, 93-97.	27.8	290
83	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20483-20488.	7.1	55
84	Embryonic stem and haematopoietic progenitor cells resist to AÎ² oligomer toxicity and maintain the differentiation potency in culture. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 137-145.	3.0	3
85	Native-unlike Long-lived Intermediates along the Folding Pathway of the Amyloidogenic Protein Î²2-Microglobulin Revealed by Real-time Two-dimensional NMR. Journal of Biological Chemistry, 2010, 285, 5827-5835.	3.4	55
86	Folding and Fibrillogenesis: Clues from Î²2-Microglobulin. Journal of Molecular Biology, 2010, 401, 286-297.	4.2	35
87	Fibrillar vs Crystalline Full-Length Î²-2-Microglobulin Studied by High-Resolution Solid-State NMR Spectroscopy. Journal of the American Chemical Society, 2010, 132, 5556-5557.	13.7	32
88	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 115-121.	3.0	5
89	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7619-7623.	7.1	63
90	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	2.3	8

#	Article	IF	Citations
91	Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis and Rheumatism, 2009, 61, 1435-1440.	6.7	100
92	Human beta-2 microglobulin W60V mutant structure: Implications for stability and amyloid aggregation. Biochemical and Biophysical Research Communications, 2009, 380, 543-547.	2.1	29
93	Topological investigation of amyloid fibrils obtained from Î²2-microglobulin. Protein Science, 2009, 11, 2362-2369.	7.6	53
94	Equilibrium Unfolding Thermodynamics of Î²2-Microglobulin Analyzed through Native-State H/D Exchange. Biophysical Journal, 2009, 96, 169-179.	0.5	20
95	Sulfonated molecules that bind a partially structured species of Î²‹sub›2‹/sub›â€microglobulin also influence refolding and fibrillogenesis. Electrophoresis, 2008, 29, 1502-1510.	2.4	18
96	Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Current Opinion in Structural Biology, 2008, 18, 771-779.	5.7	100
97	The Controlling Roles of Trp60 and Trp95 in Î²2-Microglobulin Function, Folding and Amyloid Aggregation Properties. Journal of Molecular Biology, 2008, 378, 887-897.	4.2	82
98	DE loop mutations affect Î²2-microglobulin stability and amyloid aggregation. Biochemical and Biophysical Research Communications, 2008, 377, 146-150.	2.1	36
99	Heparin Strongly Enhances the Formation of Î²2-Microglobulin Amyloid Fibrils in the Presence of Type I Collagen. Journal of Biological Chemistry, 2008, 283, 4912-4920.	3.4	108
100	Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue. Molecular and Cellular Proteomics, 2008, 7, 1570-1583.	3.8	134
101	Â2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. Nephrology Dialysis Transplantation, 2008, 24, 1176-1181.	0.7	31
102	Family developmental risk factors among adolescents with disabilities and children of parents with disabilities. Journal of Adolescence, 2007, 30, 1001-1019.	2.4	26
103	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	3.8	62
104	Molecular Dynamics Simulation Suggests Possible Interaction Patterns at Early Steps of Î²2-Microglobulin Aggregation. Biophysical Journal, 2007, 92, 1673-1681.	0.5	39
105	Human Lysozyme. , 2007, , 285-308.		17
106	Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 191-205.	3.0	124
107	Recombinant amyloidogenic domain of ApoA-I: Analysis of its fibrillogenic potential. Biochemical and Biophysical Research Communications, 2006, 351, 223-228.	2.1	18
108	Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 2006, 440, 1217-1221.	27.8	621

#	Article	IF	Citations
109	Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Science, 2006, 16, 343-349.	7.6	24
110	Micro-heterogeneity and aggregation in Î²2-microglobulin solutions: effects of temperature, pH, and conformational variant addition. European Biophysics Journal, 2006, 35, 439-445.	2.2	27
111	Collagen Plays an Active Role in the Aggregation of Î²2-Microglobulin under Physiopathological Conditions of Dialysis-related Amyloidosis*. Journal of Biological Chemistry, 2006, 281, 16521-16529.	3.4	128
112	Solution structure of Î²2-microglobulin and insights into fibrillogenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 76-84.	2.3	25
113	Limited proteolysis in the investigation of Î²2-microglobulin amyloidogenic and fibrillar states. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 44-50.	2.3	36
114	Proteomics of Î²2-microglobulin amyloid fibrils. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 23-33.	2.3	36
115	Dialysis-related amyloidosis: From molecular mechanism to therapies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 1-3.	2.3	0
116	Search of ligands for the amyloidogenic protein Î²2-microglobulin by capillary electrophoresis and other techniques. Electrophoresis, 2005, 26, 4055-4063.	2.4	17
117	A novelAÎ²PP mutation exclusively associated with cerebral amyloid angiopathy. Annals of Neurology, 2005, 58, 639-644.	5.3	81
118	Lysozyme: A paradigmatic molecule for the investigation of protein structure, function and misfolding. Clinica Chimica Acta, 2005, 357, 168-172.	1.1	74
119	Â2-Microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Science, 2005, 14, 696-702.	7.6	56
120	Pharmaceutical Strategies Against Amyloidosis: Old and New Drugs in Targeting a “Protein Misfolding Disease”. Current Medicinal Chemistry, 2004, 11, 1065-1084.	2.4	48
121	Properties of Some Variants of Human Î²2-Microglobulin and Amyloidogenesis. Journal of Biological Chemistry, 2004, 279, 9176-9189.	3.4	65
122	Capillary electrophoresis studies on the aggregation process ofÎ²-amyloid 1-42 and 1-40 peptides. Electrophoresis, 2004, 25, 3186-3194.	2.4	73
123	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology, 2004, 126, 1416-1422.	1.3	70
124	Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. Pharmacological Research, 2004, 50, 419-431.	7.1	18
125	Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1690, 33-41.	3.8	19
126	Î²2-Microglobulin H31Y Variant 3D Structure Highlights the Protein Natural Propensity Towards Intermolecular Aggregation. Journal of Molecular Biology, 2004, 335, 1051-1064.	4.2	38

#	Article	IF	Citations
127	Preliminary crystallographic characterization of the human Î²2 microglobulin His31Tyr mutant in a tetrameric assembly. Acta Crystallographica Section D: Biological Crystallography, 2003, 59, 1270-1272.	2.5	5
128	Identification and characterization of a new ligand-binding site in FnbB, a fibronectin-binding adhesin from Streptococcus dysgalactiae. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1646, 173-183.	2.3	11
129	Molecular Mechanisms of Amyloidosis. New England Journal of Medicine, 2003, 349, 583-596.	27.0	1,629
130	Conformational Switching and Fibrillogenesis in the Amyloidogenic Fragment of Apolipoprotein A-I. Journal of Biological Chemistry, 2003, 278, 2444-2451.	3.4	86
131	Structural and Folding Dynamic Properties of the T70N Variant of Human Lysozyme. Journal of Biological Chemistry, 2003, 278, 25910-25918.	3.4	23
132	Capillary electrophoresis investigation of a partially unfolded conformation of Î²2-microglobulin. Electrophoresis, 2002, 23, 918-925.	2.4	52
133	The solution structure of human Î²2â€microglobulin reveals the prodromes of its amyloid transition. Protein Science, 2002, 11, 487-499.	7.6	145
134	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Science, 2001, 10, 187-199.	7.6	44
135	Detection of two partially structured species in the folding process of the amyloidogenic protein Î²2-microglobulin. Journal of Molecular Biology, 2001, 307, 379-391.	4.2	115
136	Dynamic of Î²2â€Microglobulin Fibril Formation and Reabsorption: The Role ofâ€ƒProteolysis. Seminars in Dialysis, 2001, 14, 117-122.	1.3	23
137	Protein Aggregation. Clinical Chemistry and Laboratory Medicine, 2001, 39, 1065-75.	2.3	29
138	Hepatitis C virusâ€associated cryoglobulinaemicglomerulonephritis with delayed appearance ofmonoclonal cryoglobulinaemia. Nephrology Dialysis Transplantation, 2001, 16, 432-434.	0.7	5
139	A Partially Structured Species of Î²2-Microglobulin Is Significantly Populated under Physiological Conditions and Involved in Fibrillogenesis. Journal of Biological Chemistry, 2001, 276, 46714-46721.	3.4	137
140	Affinity capillary electrophoresis is a powerful tool to identify transthyretin binding drugs for potential therapeutic use in amyloidosis. Electrophoresis, 2000, 21, 3280-3289.	2.4	27
141	Detection of fragments of Î²2-microglobulin in amyloid fibrils. Kidney International, 2000, 57, 349-350.	5.2	22
142	Removal of the Nâ€terminal hexapeptide from human Î²2â€microglobulin facilitates protein aggregation and fibril formation. Protein Science, 2000, 9, 831-845.	7.6	263
143	Conformational dynamics of the Î²2-microglobulin C terminal in the cell-membrane-anchored major histocompatibility complex type I. Cellular and Molecular Life Sciences, 2000, 57, 675-683.	5.4	4
144	Review: Immunoglobulin Light Chain Amyloidosisâ€”The Archetype of Structural and Pathogenic Variability. Journal of Structural Biology, 2000, 130, 280-289.	2.8	179

#	Article	IF	Citations
145	4â€²-Iodo-4â€²-Deoxydoxorubicin Disrupts the Fibrillar Structure of Transthyretin Amyloid. American Journal of Pathology, 2000, 156, 1919-1925.	3.8	55
146	Biological activity and pathological implications of misfolded proteins. Cellular and Molecular Life Sciences, 1999, 55, 977.	5.4	102
147	The New Apolipoprotein A-I Variant Leu174 â†' Ser Causes Hereditary Cardiac Amyloidosis, and the Amyloid Fibrils Are Constituted by the 93-Residue N-Terminal Polypeptide. American Journal of Pathology, 1999, 155, 695-702.	3.8	108
148	Î²â€ƒ2â€microglobulin can be refolded into a native state from ex vivo amyloid fibrils. FEBS Journal, 1998, 258, 61-67.	0.2	107
149	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature, 1997, 385, 787-793.	27.8	1,061
150	Use of Anti-(beta2 Microglobulin) mAb to Study Formation of Amyloid Fibrils. FEBS Journal, 1997, 249, 21-26.	0.2	28
151	Structural and functional characterization of three human immunoglobulin Îº light chains with different pathological implications. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1317, 161-167.	3.8	18
152	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. Nephrology Dialysis Transplantation, 1996, 11, 1708-1711.	0.7	3
153	Current concepts on the pathogenesis of systemic amyloidosis. Nephrology Dialysis Transplantation, 1996, 11, 53-62.	0.7	24
154	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. Nephrology Dialysis Transplantation, 1996, 11, 1708-1711.	0.7	7
155	Molecular Mechanisms of Fibrillogenesis and the Protective Role of Amyloid P Component: Two Possible Avenues for Therapy. Novartis Foundation Symposium, 1996, 199, 73-103.	1.1	4
156	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'- iodo-4'-deoxydoxorubicin. Blood, 1995, 86, 855-861.	1.4	128
157	Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2959-2963.	7.1	198
158	Cardiac immunocyte-derived (AL) amyloidosis: An endomyocardial biopsy study in 11 patients. American Heart Journal, 1995, 130, 528-536.	2.7	50
159	Characterization of the Two Unique Human Anti-Flavin Monoclonal Immunoglobulins. FEBS Journal, 1995, 228, 886-893.	0.2	6
160	Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis.. Journal of the American Society of Nephrology: JASN, 1995, 6, 1262-1270.	6.1	13
161	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood, 1995, 86, 855-61.	1.4	27
162	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. American Journal of Hematology, 1994, 46, 189-193.	4.1	35

#	Article	IF	Citations
163	Characterization of apo(a) polymorphism by a modified immunoblotting technique in an italian population sample. Clinica Chimica Acta, 1993, 221, 159-169.	1.1	43
164	Immunobiology and pathogenesis of hepatitis C virus infection. Research in Virology, 1993, 144, 269-274.	0.7	5
165	Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications. Renal Failure, 1993, 15, 365-371.	2.1	1
166	Use of an Anti-Idiotypic Monoclonal Antibody in Studying Amyloidogenic Light Chains in Cells, Urine and Fibrils: Pathophysiology and Clinical Implications. Scandinavian Journal of Immunology, 1992, 36, 607-616.	2.7	9
167	Occurrence of monoclonal components in general practice: Clinical implications. European Journal of Haematology, 1992, 48, 192-195.	2.2	45
168	Defect of Platelet Aggregation and Adhesion Induced by Autoantibodies Against Platelet Glycoprotein IIIa. Thrombosis and Haemostasis, 1992, 68, 208-213.	3.4	24
169	Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1991, 1097, 177-182.	3.8	29
170	A Case of IgM(Â) Monoclonal Gammopathy Simulating an IgM-IgG Biclonal Gammopathy. Annals of Clinical Biochemistry, 1990, 27, 158-160.	1.6	0
171	Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. British Journal of Haematology, 1990, 74, 65-69.	2.5	65
172	Structural characterization of Îº II Inc, a new amyloid immunoglobulin. BBA - Proteins and Proteomics, 1989, 995, 103-108.	2.1	12
173	Study of three patients with monoclonal gammopathies and â€˜lupus-likeâ€™ anticoagulants. British Journal of Haematology, 1989, 73, 221-227.	2.5	57
174	Selective bone marrow involvement of lymphoplasmacytic cells secreting monoclonal IgA rheumatoid factor in a patient with Sjogren's syndrome and serum hyperviscosity.. Annals of the Rheumatic Diseases, 1987, 46, 938-942.	0.9	5
175	Characteristics of a ferritinâ€binding protein present in human serum. British Journal of Haematology, 1987, 65, 489-493.	2.5	30
176	Use of a monoclonal antibody against human heart ferritin for evaluating acidic ferritin concentration in human serum. British Journal of Haematology, 1985, 61, 445-453.	2.5	19
177	Immunological Reactivity of Serum Ferritin in Patients with Malignancy. Tumori, 1985, 71, 547-554.	1.1	23
178	Immunoassay methods for determination of serum C-reactive protein levels. Research in Clinic and Laboratory, 1984, 14, 581-585.	0.3	0
179	Lysozyme. , 0, , 635-656.		5